October 20, 2023 07:14 AM EDTUpdated 10:43 AM
Deals

#ES­MO23 dis­patch: What to know about the HER3 ADC that got Mer­ck to pay $2B cash

Reynald Castañeda

Deputy Editor

MADRID — Among the three an­ti­body-drug con­ju­gates from Mer­ck’s deal with Dai­ichi Sankyo, pa­tri­tum­ab derux­te­can takes up the largest por­tion of the $4 bil­lion up­front …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times